Imres B.v. Pharmaceutical Import Profile — Netherlands (DGFT 2022–2026)

Name: Imres B.v. Pharmaceutical Import Records from India — 3 Products, $919.3K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Imres B.v. — Pharmaceutical Importer Profile (2026) | 3 Products, $919.3K Trade | TransData Nexus

Imres B.v.

Pharmaceutical Importer · Netherlands · CNS & Psychiatric Focus · $919.3K Total Trade · DGFT Verified

Imres B.v. is a pharmaceutical importer based in Netherlands with a total trade value of $919.3K across 3 products in 3 therapeutic categories. Based on 54 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Imres B.v. sources from 28 verified Indian suppliers, with Otsuka Pharmaceutical India Private Limited accounting for 28.3% of imports.

Imres B.v. — Import Portfolio & Supplier Network

Imres B.v. import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Imres B.v.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Otsuka Pharmaceutical India Private Limited	$1.9M	161	28.3%
Milan Laboratories (india) Private Limited	$1.2M	74	18.3%
Macleods Pharmaceuticals Limited

What Formulations Does Imres B.v. Import?

Formulation	Value	Ships
Compound sodium lactate intravenous	$390.9K	17
Fluoxetine capsules USP 20 MG (10x10s)	$252.1K	6
Artesunate injection 60MG powder for INJ	$250.0K	5
Glucose intravenous infusion BP (50 g/l)	$232.7K	8
Pharma. goods/harmless	$226.5K	9
Tranexamic acid injection 100MG/ML	$181.5K	6
Sodium chloride intravenous infusion	$178.0K	8
Sterilised water for injections BP 5ML	$144.6K	9
Sterilised water for injections BP 10 ML	$137.5K	3
Sodium chloride and glucose	$116.2K	6
Sodium chloride intravenous infusion	$101.3K	3
Pharma. goods/harmless	$100.0K	2
Hydrocortisone sodium succinate 100MG	$98.9K	2
Amoxicillin 250MG dispersible	$87.1K	2
Harmless medicines tetracycline	$86.6K	6

Imres B.v. imports 229 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Fluoxetine	CNS & Psychiatric	$350.0K	7	0.1%	4
2	Salicylic	Combination Drugs	$349.7K	35	2.1%	8
3	Tetracycline	Antibiotics	$219.6K	12	1.3%	10

Imres B.v. imports 3 pharmaceutical products across 3 categories into Netherlands totaling $919.3K.

Imres B.v. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Imres B.V., established in 1980, is a Dutch company specializing in the wholesale distribution of medical relief, particularly for disaster relief. Headquartered in Lelystad, Flevoland, the Netherlands, Imres has over 35 years of experience in providing high-quality medical solutions to Non-Governmental Organizations (NGOs), governmental bodies, and private organizations. In October 2014, Imres became part of Imperial Holdings International B.V., a global logistics and supply chain company. (dealmaker.nl)

The company's product portfolio includes pharmaceuticals, medical consumables, kits, and hospital equipment. Imres is known for its stringent quality control measures, including independent testing in World Health Organization (WHO) pre-qualified and ISO/IEC 17025:2005 certified laboratories. (imres.nl) With a dedicated and experienced staff, Imres provides a one-stop procurement service and a 24-hour response service in emergency situations.

2Distribution Network

Imres operates a state-of-the-art 6,500 square meter climate-controlled warehouse in Lelystad, which is Good Distribution Practice (GDP) and Good Storage Practice (GSP) certified. This facility enables the company to manage a diverse range of medical products efficiently. Imres has offices in the Netherlands, Dubai, India, Canada, China, and the Democratic Republic of Congo, facilitating its global distribution network. (clodura.ai) The company's logistics capabilities support direct shipment, distribution, emergency shipment, and packing services, ensuring timely delivery to various regions.

3Industry Role

Imres B.V. functions primarily as a medical wholesaler, specializing in the distribution of pharmaceuticals, medical kits, equipment, and disposables. The company plays a crucial role in supplying medical relief, particularly in disaster-stricken areas, by providing essential medical supplies to NGOs, governmental bodies, and private organizations. Imres's extensive experience and commitment to quality make it a trusted partner in the global healthcare supply chain.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Imres B.v.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Imres B.V. imports a total of $919K USD worth of finished pharmaceutical formulations from India, comprising 54 shipments across three therapeutic categories. The top five products imported are Fluoxetine ($350K), Salicylic ($350K), and Tetracycline ($220K), accounting for 100% of the company's imports from India. This indicates a high level of sourcing concentration, with a significant dependency on a limited number of products.

The shipment data reveals that Imres maintains relationships with 28 unique Indian suppliers, with the top five suppliers being Otsuka Pharmaceutical India Private Limited ($1.9M), Milan Laboratories (India) Private Limited ($1.2M), Macleods Pharmaceuticals Limited ($708K), Micro Labs Limited ($509K), and Medreich Limited ($378K). This diversified supplier base suggests a strategic approach to mitigate risks associated with single-source dependency. However, the concentration of imports in a few products may expose Imres to supply chain disruptions if any of these products face production or regulatory challenges.

2Supply Chain Resilience

Imres B.V.'s supply chain resilience is supported by its diversified supplier base, encompassing 28 unique Indian suppliers. This diversification reduces the risk associated with single-source dependency. The company's stringent quality control measures, including independent testing in WHO pre-qualified and ISO/IEC 17025:2005 certified laboratories, further enhance supply chain reliability. (imres.nl) Additionally, Imres's state-of-the-art climate-controlled warehouse in Lelystad, certified for GDP and GSP, ensures optimal storage conditions for pharmaceutical products.

Importing Pharmaceuticals into Netherlands — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Netherlands

1Regulatory Authority & Framework

In the Netherlands, the Dutch Medicines Evaluation Board (CBG) is the primary regulatory authority responsible for the evaluation and supervision of medicines. The key legislation governing pharmaceutical imports includes the Medicines Act (Geneesmiddelenwet), which outlines the requirements for the import, distribution, and sale of medicinal products. The marketing authorization pathway for Indian generics involves obtaining a marketing authorization from the CBG, which may include a mutual recognition procedure or decentralized procedure, depending on the product's characteristics and intended market.

2Import Licensing & GMP

Import licensing requirements in the Netherlands stipulate that all medicinal products must be authorized by the CBG before being imported and placed on the market. Manufacturers and importers must comply with Good Manufacturing Practice (GMP) standards, which are recognized by the European Medicines Agency (EMA) and the World Health Organization (WHO). GMP certificates from these organizations are generally accepted by the CBG. Additionally, importers must hold a wholesale distribution authorization issued by the CBG, ensuring compliance with GDP and GSP standards.

Quality & Labeling

Imres B.v. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Imres B.V.'s focus on importing specific therapeutic categories—CNS & Psychiatric (38.1%), Combination Drugs (38.0%), and Antibiotics (23.9%)—aligns with global health priorities and the company's mission to provide essential medical supplies to regions in need. The high import values of Fluoxetine, Salicylic, and Tetracycline indicate significant demand for these products in the Netherlands, driven by factors such as disease prevalence, treatment protocols, and public health initiatives.

2Sourcing Profile

Imres B.V. employs a sourcing strategy that emphasizes quality and reliability, as evidenced by its stringent vendor rating system and adherence to international quality standards. The company's preference for finished pharmaceutical formulations, rather than raw Active Pharmaceutical Ingredients (APIs), suggests a focus on ready-to-use products that meet the specific needs of its target markets. India's established pharmaceutical manufacturing capabilities and compliance with international quality standards make it a suitable sourcing partner for Imres.

3Market Positioning

Based on its product mix, Imres B.V. serves multiple segments of the Netherlands market, including retail pharmacies, hospitals, government tenders, and wholesale distribution. The company's diverse product portfolio and focus on essential medicines enable it to meet the needs of various healthcare providers and organizations, positioning it as a key player in the Dutch pharmaceutical supply chain.

Seller's Guide — How to Become a Supplier to Imres B.v.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Dutch market by offering high-quality finished pharmaceutical formulations that align with Imres B.V.'s product focus. Gaps in Imres's current sourcing may exist in specific therapeutic areas or formulations not currently imported. Indian exporters can explore these opportunities by ensuring compliance with Dutch regulatory requirements and demonstrating the quality and reliability of their products.

2Requirements & Qualifications

Indian exporters seeking to supply Imres B.V. and the Netherlands market must obtain marketing authorization from the CBG, comply with GMP standards recognized by the EMA and WHO, and hold a wholesale distribution authorization. Products must meet batch testing and stability requirements, and labeling must be in Dutch, including all necessary information as specified by the CBG. Compliance with serialization mandates may also be required.

3How to Approach

Frequently Asked Questions — Imres B.v.

What products does Imres B.v. import from India?

Imres B.v. imports 3 pharmaceutical products across 3 categories. Top imports: Fluoxetine ($350.0K), Salicylic ($349.7K), Tetracycline ($219.6K).

Who supplies pharmaceuticals to Imres B.v. from India?

Imres B.v. sources from 28 verified Indian suppliers. The primary supplier is Otsuka Pharmaceutical India Private Limited (28.3% of imports, $1.9M).

What is Imres B.v.'s total pharmaceutical import value?

Imres B.v.'s total pharmaceutical import value from India is $919.3K, based on 54 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Imres B.v. focus on?

Imres B.v. imports across 3 categories. The largest: CNS & Psychiatric (38.1%), Combination Drugs (38.0%), Antibiotics (23.9%).

Get Full Imres B.v. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.